Intech Investment Management LLC Sells 33,704 Shares of Lantheus Holdings, Inc. $LNTH

Intech Investment Management LLC trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 34.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 63,372 shares of the medical equipment provider’s stock after selling 33,704 shares during the period. Intech Investment Management LLC’s holdings in Lantheus were worth $3,250,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its stake in Lantheus by 18.8% in the second quarter. Envestnet Asset Management Inc. now owns 147,582 shares of the medical equipment provider’s stock worth $12,081,000 after purchasing an additional 23,396 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Lantheus during the second quarter valued at $654,000. Los Angeles Capital Management LLC grew its holdings in shares of Lantheus by 63.2% in the second quarter. Los Angeles Capital Management LLC now owns 11,892 shares of the medical equipment provider’s stock worth $973,000 after purchasing an additional 4,607 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Lantheus by 20.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after purchasing an additional 212 shares during the last quarter. Finally, CSM Advisors LLC purchased a new position in Lantheus in the 2nd quarter worth about $370,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 1.9%

Shares of NASDAQ LNTH opened at $76.30 on Tuesday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The stock’s fifty day simple moving average is $68.31 and its two-hundred day simple moving average is $60.39. The stock has a market capitalization of $4.93 billion, a PE ratio of 22.64 and a beta of -0.11. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the prior year, the business posted $1.59 EPS. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research analyst reports. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday. Finally, Mizuho raised their price target on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.